EB-CAR5-NK

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameEB-CAR5-NK

Drug Alias NameEB-CAR5-NK

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cell replacementsT-cell surface glycoprotein CD5 modulators

TargetsT-cell surface glycoprotein CD5

Therapy Area/IndicationsThymoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesBeijing Biotech

China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biotech

Inactive CompaniesN/A

Active IndicationsThymoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A